Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer
ASCO
https://meetinglibrary.asco.org/record/187856/abstract
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine – Will it affect clinicians – Quincy S. Chu MD – University of Alberta @UAlberta #advancedcancer #metasta…
